MapLight director granted RSUs and stock options

MapLight Therapeutics director Troy Cox received new equity awards as part of non-employee director compensation.

Rhea-AI Filing Summary

MapLight Therapeutics director Troy Cox received new equity awards as part of non-employee director compensation. He was granted 7,864 restricted stock units, each representing one share of voting common stock. These RSUs vest in three equal annual installments beginning on June 23, 2027, contingent on his continued service.

He was also granted a stock option covering 29,804 shares of voting common stock at an exercise price of $28.64 per share, vesting on the same three-year schedule starting June 23, 2027. After these grants, his reported direct holdings include 7,864 shares from RSUs and 29,804 underlying option shares.

Insider Trade Summary

Grant/Award: 37,668 shares

Grant/Award 2 txns

Insider Cox Troy

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	29,804	$0.00	$0.00
Grant/Award	Voting Common Stock	7,864	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 29,804 contracts (Direct); Voting Common Stock — 7,864 shares (Direct)

Footnotes (3)

1. F1. Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The RSUs will vest in three equal annual installments beginning on June 23, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy.
2. F2. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.
3. F3. Represents a stock option granted pursuant to the Plan. The shares subject to this stock option will vest in three equal annual installments beginning on June 23, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy.

Key Figures

RSUs granted: 7,864 units Options granted: 29,804 shares Option exercise price: $28.64 per share +4 more

7 metrics

RSUs granted 7,864 units Restricted stock units granted June 23, 2026

Options granted 29,804 shares Stock option grant June 23, 2026

Option exercise price $28.64 per share Stock option on Voting Common Stock

RSU vesting start June 23, 2027 First of three equal annual installments

Option vesting end Three annual installments Beginning June 23, 2027, subject to Continuous Service

Shares held after RSU grant 7,864 shares Voting Common Stock following RSU award

Underlying option shares after grant 29,804 shares Voting Common Stock underlying option after grant

Key Terms

restricted stock units, 2025 Equity Incentive Plan, Continuous Service, non-employee director compensation policy, +1 more

5 terms

restricted stock units financial

"Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2025 Equity Incentive Plan financial

"granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan")"

Continuous Service financial

"subject to the Continuous Service (as defined in the Plan) of the Reporting Person"

non-employee director compensation policy financial

"This grant was made pursuant to the Issuer's non-employee director compensation policy"

stock option financial

"Represents a stock option granted pursuant to the Plan"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MapLight Therapeutics (MPLT) report for Troy Cox?

MapLight Therapeutics reported that director Troy Cox received equity compensation. He was granted 7,864 restricted stock units and a stock option for 29,804 shares, both under the 2025 Equity Incentive Plan, rather than buying shares in the open market.

How many RSUs did Troy Cox receive from MapLight Therapeutics (MPLT)?

Troy Cox received 7,864 restricted stock units from MapLight Therapeutics. Each RSU represents a contingent right to receive one share of voting common stock, subject to vesting conditions tied to his continued service on the board over three years.

What are the terms of Troy Cox’s stock option grant at MapLight Therapeutics (MPLT)?

Troy Cox received a stock option covering 29,804 shares of voting common stock at an exercise price of $28.64 per share. The option vests in three equal annual installments starting June 23, 2027, subject to his continued service as defined in the company’s plan.

When do Troy Cox’s RSUs and options from MapLight Therapeutics (MPLT) vest?

Both the RSUs and stock options granted to Troy Cox vest in three equal annual installments beginning June 23, 2027. Vesting requires that he maintain Continuous Service, as defined in MapLight Therapeutics’ 2025 Equity Incentive Plan, on each applicable vesting date.

Is Troy Cox’s MapLight Therapeutics (MPLT) Form 4 transaction a share purchase?

No, the Form 4 shows compensation-related equity grants, not a market purchase. Troy Cox received restricted stock units and a stock option under the non-employee director compensation policy, with no cash price paid per share in the reported transactions.

How many MapLight Therapeutics (MPLT) shares does Troy Cox hold after these grants?

Following the June 23, 2026 grants, Troy Cox holds 7,864 shares of Voting Common Stock from RSUs and an option for 29,804 underlying shares. These positions reflect his direct ownership as reported in the Form 4 filing for that date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/25/2026 - 06:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cox Troy

(Last) (First) (Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Stock	06/23/2026		A		7,864(1)	A	$0(2)	7,864	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$28.64	06/23/2026		A		29,804		(3)	06/22/2036	Voting Common Stock	29,804	$0	29,804	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The RSUs will vest in three equal annual installments beginning on June 23, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy.

2. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.

3. Represents a stock option granted pursuant to the Plan. The shares subject to this stock option will vest in three equal annual installments beginning on June 23, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)